The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
Open accessAbstract
OBJECTIVES: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with important differences in cost-effectiveness. DATA SOURCES: Bibliographic databases were searched from inception to March 2007 for literature on the effectiveness and cost-effectiveness of prophylaxis with palivizumab. REVIEW METHODS: The literature was systematically reviewed and current economic evaluations were analysed to identify which parameters were driving the different cost-effectiveness estimates. A probabilistic decision-analytical model was built to assess the cost-effectiveness of prophylaxis with palivizumab for children at risk of RSV infection and the parameters populated with the best estimates thought most applicable to the UK. We also constructed a new model, the Birmingham Economic Evaluation (BrumEE). Cost-effectiveness analyses were undertaken from both NHS and societal perspectives. RESULTS: Two randomised controlled trials (RCTs) were identified. Prophylaxis with palivizumab for preterm infants without chronic lung disease (CLD) or children with CLD resulted in a 55% reduction in RSV hospital admission: 4.8% (48/1002) in the palivizumab group and 10.6% (53/500) in the no prophylaxis group (p = 0.0004). Prophylaxis with palivizumab was associated with a 45% reduction in hospitalisation rate RSV among children with coronary heart disease (CHD). Hospitalisation rates for RSV were 5.3% (34/639) in the palivizumab group and 9.7% (63/648) in the no prophylaxis group (p = 0.003). Of existing economic evaluations, 3 systematic reviews and 18 primary studies were identified. All the systematic reviews concluded that the potential costs of palivizumab were far in excess of any potential savings achieved by decreasing hospital admission rates, and that the use of palivizumab was unlikely to be cost-effective in all children for whom it is recommended, but that its continued use for particularly high-risk children may be justified. The incremental cost-effectiveness ratios (ICERs) of the primary studies varied 17-fold for life-years gained (LYG), from 25,800 pounds/LYG to 404,900 pounds/LYG, and several hundred-fold for quality-adjusted life-years (QALYs), from 3200 pounds/QALY to 1,489,700 pounds/QALY for preterm infants without CLD or children with CLD. For children with CHD, the ICER varied from 5300 pounds/LYG to 7900 pounds/LYG and from 7500 pounds/QALY to 68,700 pounds/QALY. An analysis of what led to the discrepant ICERs showed that the assumed mortality rate for RSV infection was the most important driver. The results of the BrumEE confirm that palivizumab does not reach conventional levels of cost-effectiveness in any of the licensed indications if used for all eligible children. CONCLUSIONS: Prophylaxis with palivizumab is clinically effective for the reducing the risk of serious lower respiratory tract infection caused by RSV infection and requiring hospitalisation in high-risk children, but if used unselectively in the licensed population, the ICER is double that considered to represent good value for money in the UK. The BrumEE shows that prophylaxis with palivizumab may be cost-effective (based on a threshold of 30,000 pounds/QALY) for children with CLD when the children have two or more additional risk factors. Future research should initially focus on reviewing systematically the major uncertainties for patient subgroups with CLD and CHD and then on primary research to address the important uncertainties that remain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Evaluating patient-based outcome measures for use in clinical trials.
Fitzpatrick, Davey, Buxton, & Jones (1998) · Health Technology Assessment · doi:10.3310/hta2140 · Cited by 1,715
Qualitative research methods in health technology assessment: a review of the literature.
Murphy, Dingwall, Greatbatch, Parker, & Watson (1998) · Health Technology Assessment · doi:10.3310/hta2160 · Cited by 1,107
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Quality-of-life measures in chronic diseases of childhood
Eiser, C., & Morse, R. (2001) · Health Technology Assessment · doi:10.3310/hta5040 · Cited by 872
Moher, D., Pham, B., Lawson, M., & Klassen, T. (2003) · Health Technology Assessment · doi:10.3310/hta7410 · Cited by 500
Oliver, S., Clarke-Jones, L., Rees, R., Milne, R., Buchanan, P., Gabbay, J., Gyte, G., Oakley, A., & Stein, K. (2004) · Health Technology Assessment · doi:10.3310/hta8150 · Cited by 400
Churchill, R., Hunot, V., Corney, R., Knapp, M., McGuire, H., Tylee, A., & Wessely, S. (2002) · Health Technology Assessment · doi:10.3310/hta5350 · Cited by 368
Kaltenthaler, E., Brazier, J., De Nigris, E., Tumur, I., Ferriter, M., Beverley, C., Parry, G., Rooney, G., & Sutcliffe, P. (2006) · Health Technology Assessment · doi:10.3310/hta10330 · Cited by 357
Elkan, Kendrick, Hewitt, Robinson, Tolley, Blair, Dewey, Williams, & Brummell (2000) · Health Technology Assessment · doi:10.3310/hta4130 · Cited by 297
Royle, P., & Waugh, N. (2003) · Health Technology Assessment · doi:10.3310/hta7340 · Cited by 194
Psychological treatment for insomnia in the regulation of long-term hypnotic drug use
Morgan, K., Dixon, S., Mathers, N., Thompson, J., & Tomeny, M. (2004) · Health Technology Assessment · doi:10.3310/hta8080 · Cited by 166
Issues in methodological research: perspectives from researchers and commissioners
Lilford, R. J., Richardson, A., Stevens, A., Fitzpatrick, R., Edwards, S., Rock, F., & Hutton, J. L. (2001) · Health Technology Assessment · doi:10.3310/hta5080 · Cited by 132
Cited by
Riegel, B., Moser, D. K., Anker, S. D., Appel, L. J., Dunbar, S. B., Grady, K. L., Gurvitz, M. Z., Havranek, E. P., Lee, C. S., Lindenfeld, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192628 · Cited by 961
Evidence-based clinical guidelines for immigrants and refugees
Pottie, K., Greenaway, C., Feightner, J., Welch, V., Swinkels, H., Rashid, M., Narasiah, L., Kirmayer, L. J., Ueffing, E., MacDonald, N. E., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.090313 · Cited by 526
WRITING COMMITTEE MEMBERS, Mark, D. B., Berman, D. S., Budoff, M. J., Carr, J. J., Gerber, T. C., Hecht, H. S., Hlatky, M. A., Hodgson, J. M., Lauer, M. S., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181d4b618 · Cited by 388
Bronchiolitis: Recent Evidence on Diagnosis and Management
Zorc, J. J., & Hall, C. B. (2010) · Pediatrics · doi:10.1542/peds.2009-2092 · Cited by 341
The estimated prevalence and incidence of late stage age related macular degeneration in the UK
Owen, C. G., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A. E., & Rudnicka, A. R. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301109 · Cited by 319
Metadata
- Authors
- Wang, D., Cummins, C., Bayliss, S., Sandercock, J., & Burls, A.
- Venue
- Health Technology Assessment
- Published
- 2008-12
- Volume
- 12
- Issue
- 36
- Pages
- iii, ix-x, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1976501464
- Cited by
- 175
- References
- 13
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.